Skip to main content

CovalX Inks Deal with ASPEC to Sell Protein Analysis Tech in Greater China Market

Premium

CovalX and ASPEC Technologies said this week that they have signed a distribution agreement to sell CovalX's mass spec-based protein interaction and protein characterization tools into the greater China market.

The agreement combines CovalX's products with ASPEC's commercial partnerships and infrastructure in this region, providing ASPEC customers with exclusive access to CovalX's protein analysis tools, the companies said.

CovalX's MALDI mass spec-based HM3 platform allows for protein-protein analyses including stoichiometry, biotherapeutic aggregation, epitope mapping, and immunocomplex characterization.

The deal covers ASPEC customers in mainland China, Hong Kong, Macau and Taiwan. Financial and other terms were not disclosed.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.